ABSTRACT
Purposes: This study aimed to investigate the efficacy of ultrasound (US)-, computed tomography (CT)-, and magnetic resonance imaging (MRI)-guided radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC). Materials and Methods: This retrospective study included 141 patients with HCC who were treated with US-guided (n = 29), CT-guided (n = 50), or MRI-guided RFA (n = 62). The primary endpoint was progression-free survival (PFS). The secondary endpoints included overall survival (OS), technique success (TS), and technique efficacy (TE). Cox model and logistic regression were used to determine the risk factors for tumor recurrence and TE. Results: The US, CT, and MRI groups did not show a significant difference in terms of baseline variables. The three groups did not differ significantly in PFS rate (P = 0.072) and OS rate (P = 0.231). The PFS rates at 3 years for the US, CT, and MRI groups were 40.90%, not reached, and 14.80%, respectively. The OS rates at 3 years were 94.70%, 97.50%, and 85.50% for US, CT, and MRI groups, respectively. No significant differences were observed between the three groups in terms of TS rate (P = 0.113) and TE rate (P = 0.682). In multivariate analysis, liver cirrhosis (P = 0.001), level of alpha-fetoprotein (AFP, P = 0.004), and number of tumors (P = 0.012) were independent risk factors for PFS. For TE, the level of AFP (P = 0.018) was an independent factor. Conclusion: US-, CT-, and MRI-guided RFA was effective for treating HCC patients. Liver cirrhosis, AFP level, and tumor number were associated with tumor recurrence, and the level of AFP was an independent risk factor affecting TE
ABSTRACT
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatobiliary cancer after hepatocellular carci-noma (HCC). Surgical resection is the main curative treatment for ICC. Patients with ICC exhibit poorer prognosis compared with those with HCC. A comprehensive individualized prognostic system must be developed based on specific factors of patients. Several distinct prognostic staging systems have been proposed for patients with ICC treated by surgery. These systems include six staging systems, two scoring systems, and three prognostic nomograms. However, all of these prognostic systems are based on data from patients un-dergoing surgery resection and have not been validated in patients receiving other therapies. In this review, we will discuss the prog-nostic accuracy and applicability of current available prognostic systems and provide directions for future investigations.
ABSTRACT
Hepatectomy is one of the curative therapies for hepatocellular carcinoma (HCC). However, the 5-year recurrence rate after resection is higher as 70%, and the 5-year survival rate is less than 50%. Furthermore, there is no consensus about the treatment strategy for recurrent HCC after hepatectomy. To our knowledge, radiofrequency ablation (RFA) has been widely applied, either with curative or palliative intention. And it is a feasible treatment for recurrent HCC because of majority of the recurrent HCCs with diameter less than 3 cm. The therapeutic efficacy after RFA is similar to re-resection with several advantages, such as minimal invasion, less complications and short hospitalization duration. This study discusses the feasibility of RFA which is used to treat recurrent small HCC, aiming at providing information for promoting the treatment efficacy of recurrent small HCC.